{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:38:59Z","timestamp":1782265139779,"version":"3.54.5"},"reference-count":82,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.leukres.2014.05.007","type":"journal-article","created":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T15:17:00Z","timestamp":1400339820000},"page":"1145-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8657","authenticated-orcid":false,"given":"M.","family":"Heiblig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sobh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.05.007_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2014.05.007_bib0010","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2014.05.007_bib0020","first-page":"S11","article-title":"Resistance and relapse with imatinib in CML: causes and consequences","volume":"6","author":"Deininger","year":"2008","journal-title":"J Natl Comprehen Cancer Network: JNCCN"},{"key":"10.1016\/j.leukres.2014.05.007_bib0025","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0030","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0035","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation","volume":"110","author":"de Lavallade","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6513","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant\/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Nicolini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2014.05.007_bib0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","article-title":"Homoharringtonine: history, current research, and future direction","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.05.007_bib0050","first-page":"841","article-title":"Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China","volume":"71","author":"Huang","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2014.05.007_bib0055","first-page":"263","article-title":"Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment","volume":"2","author":"Group CRC","year":"1976","journal-title":"Chin Med J"},{"key":"10.1016\/j.leukres.2014.05.007_bib0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0040-4039(01)97839-6","article-title":"Structures of harringtonine, isoharringtonine, and homoharringtonine","author":"Powell","year":"1970","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.leukres.2014.05.007_bib0065","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/jps.2600610812","article-title":"Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity","volume":"61","author":"Powell","year":"1972","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.leukres.2014.05.007_bib0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.12.2.298","article-title":"Cytotoxicity and cell cycle specificity of homoharringtonine","volume":"12","author":"Baaske","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.leukres.2014.05.007_bib0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00258117","article-title":"Biologic and pharmacologic effects of harringtonine on human leukemia\u2013lymphoma cells","volume":"14","author":"Takemura","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","article-title":"Inhibition of translation in eukaryotic systems by harringtonine","volume":"72","author":"Fresno","year":"1977","journal-title":"Euro J Biochem\/FEBS"},{"key":"10.1016\/j.leukres.2014.05.007_bib0085","first-page":"131","article-title":"The antitumor effects and pharmacologic actions of harringtonine","volume":"3","author":"Department of Pharmacology IoMM","year":"1977","journal-title":"Chin Med J"},{"key":"10.1016\/j.leukres.2014.05.007_bib0090","first-page":"2031","article-title":"Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro","volume":"50","author":"Zhou","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.05.007_bib0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","article-title":"Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells","volume":"5","author":"Tang","year":"2006","journal-title":"Mol Cancer Thera"},{"key":"10.1016\/j.leukres.2014.05.007_bib0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nchembio.2007.59","article-title":"High-content single-cell drug screening with phosphospecific flow cytometry","volume":"4","author":"Krutzik","year":"2008","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0110","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-262808","article-title":"Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/leu.2011.380","article-title":"Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common beta-subunit c of cytokine receptors","volume":"26","author":"Klag","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0125","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1101\/gad.13.15.1899","article-title":"BCL-2 family members and the mitochondria in apoptosis","volume":"13","author":"Gross","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.leukres.2014.05.007_bib0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12185-008-0081-8","article-title":"Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin","volume":"87","author":"Kuroda","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/138161211795049778","article-title":"Omacetaxine as an anticancer therapeutic: what is old is new again","volume":"17","author":"Wetzler","year":"2011","journal-title":"Curr Pharma Des"},{"key":"10.1016\/j.leukres.2014.05.007_bib0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1755-8794-5-37","article-title":"Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines","volume":"5","author":"Kulkarni","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.leukres.2014.05.007_bib0145","first-page":"1085","article-title":"Phase I clinical investigation of homoharringtonine","volume":"68","author":"Legha","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.leukres.2014.05.007_bib0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.05.007_bib0155","article-title":"Semi-synthetic homoharringtonine (MyelostatVR) for chronic myeloid leukemia in accelerated phase after imatinib failure","volume":"102","author":"Burton","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0160","article-title":"Subcutaneous hemi-synthetic homoharringtonine (HHT) in combination with imatinib mesylate (Gleevec) in patients (PTS) with STI-resistant chronic myelogenous leukemia (CML): preliminary results of a pilot study","volume":"102","author":"Maloisel","year":"2003","journal-title":"Blood (Annu Meet Abs)"},{"key":"10.1016\/j.leukres.2014.05.007_bib0165","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O\u2018Brien","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0170","first-page":"422","article-title":"Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data","volume":"96","author":"Nanda","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0175","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors\u2014results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood (Annu Meet Abs)"},{"key":"10.1016\/j.leukres.2014.05.007_bib0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","article-title":"Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors","volume":"71","author":"Nemunaitis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0185","first-page":"1403","article-title":"Clinical pharmacology of homoharringtonine","volume":"70","author":"Savaraj","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.leukres.2014.05.007_bib0190","first-page":"274","article-title":"The metabolism of homoharringtonine by liver microsomes of rats and rabbits","volume":"26","author":"Cui","year":"1991","journal-title":"Yao xue xue bao=Acta Pharma Sinica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00162769","article-title":"Central nervous system (CNS) penetration of homoharringtonine (HHT)","volume":"5","author":"Savaraj","year":"1987","journal-title":"J Neuro-oncol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0205","first-page":"144","article-title":"Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"34","author":"Pei","year":"2013","journal-title":"Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi"},{"key":"10.1016\/j.leukres.2014.05.007_bib0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol\/Educ Programe Am Soc Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2014.05.007_bib0215","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0220","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0225","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0235","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0240","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.05.007_bib0245","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.05.007_bib0250","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0255","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0260","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0265","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3324\/haematol.2012.068890","article-title":"The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0270","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0275","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"Itonaga","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0285","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/10428194.2013.812788","article-title":"Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy","volume":"55","author":"Ilander","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2014.05.007_bib0290","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.05.007_bib0295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/leu.2012.186","article-title":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2018Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2014.05.007_bib0305","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.05.007_bib0310","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"1","author":"Speck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2014.05.007_bib0315","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2014.05.007_bib0320","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0325","first-page":"114","article-title":"Impact of allogeneic stem cell transplantation as salvage therapy after T315I mutation detection in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients","author":"Nicolini","year":"2009","journal-title":"Blood (Ann Meet Abs)"},{"key":"10.1016\/j.leukres.2014.05.007_bib0330","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00180819","article-title":"A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer","volume":"14","author":"Witte","year":"1996","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.leukres.2014.05.007_bib0340","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1006327418043","article-title":"A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer","volume":"17","author":"Witte","year":"1999","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.leukres.2014.05.007_bib0345","first-page":"1189","article-title":"Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia","volume":"6","author":"Feldman","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0350","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2014.05.007_bib0355","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","article-title":"Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia","volume":"93","author":"O\u2018Brien","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0360","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","article-title":"Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia","volume":"94","author":"O\u2018Brien","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.05.007_bib0365","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3109\/10428194.2012.745521","article-title":"Long-term effect of interferon-alpha combined with homoharringtonine on chronic myelogenous leukemia in chronic phase","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuke Lymph"},{"key":"10.1016\/j.leukres.2014.05.007_bib0370","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.05.007_bib0375","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.11620","article-title":"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase","volume":"98","author":"O\u2018Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.05.007_bib0380","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin Lymph, Myeloma Leuke"},{"key":"10.1016\/j.leukres.2014.05.007_bib0385","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.3324\/haematol.2012.083006","article-title":"Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.05.007_bib0390","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.05.007_bib0395","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.05.007_bib0400","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","article-title":"The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge","volume":"10","author":"Nicolini","year":"2010","journal-title":"Clin Lymph, Myeloma Leuke"},{"key":"10.1016\/j.leukres.2014.05.007_bib0405","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2011.09016.x","article-title":"Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation","volume":"157","author":"Coude","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2014.05.007_bib0410","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T06:19:17Z","timestamp":1689229157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614001489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0145212614001489"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.05.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}